Severe immune-mediated myocarditis induced by Tislelizumab combined with Disitamab Vedotin: a case report
10.3760/cma.j.cn112330-20241028-00480
- VernacularTitle:替雷利珠单抗联合维迪西妥单抗治疗尿路上皮癌致严重免疫性心肌炎1例报告
- Author:
Haojie CHEN
1
;
Jie HAN
1
;
Kang SHAO
1
;
Liulin LI
1
;
Yan XU
1
;
Lin YUAN
1
Author Information
1. 南京中医药大学附属医院泌尿外科，南京 210029
- Publication Type:Journal Article
- Keywords:
Tislelizumab;
Disitamab Vedotin;
Upper tract urothelial carcinoma;
Immune-mediated myocarditis;
Immune-related adverse events
- From:
Chinese Journal of Urology
2025;46(4):300-302
- CountryChina
- Language:Chinese
-
Abstract:
Immune-mediated myocarditis is a rare but life-threatening complication of immune checkpoint inhibitor therapy. We report a case of a patient with high-grade urothelial carcinoma and lymph node metastasis. After exhibiting cisplatin intolerance postoperatively, the patient received dual immunotherapy. On day 19 of treatment, following physical exertion, the patient developed progressive chest tightness and dyspnea, accompanied by markedly elevated cardiac biomarkers (troponin Ⅰ: 550.7 pg/mL; creatine kinase: 9 669 U/L). Multidisciplinary evaluation confirmed the diagnosis of grade 4 immune-mediated myocarditis. Immediate discontinuation of immunotherapy was followed by intensive care unit admission for hormonal shock therapy and additional symptomatic management. After two months of targeted management, both clinical symptoms and laboratory parameters normalized. The patient remained stable with no cardiac sequelae during three-month post-discharge follow-up.
